Recent inspection trends and industry direction in Australia indicate a more critical review of validation and qualification activities across GMP-regulated environments. The Therapeutic Goods Administration (TGA) is increasingly focused on how well organisations apply risk-based principles and whether validation truly reflects operational reality.
This shift is particularly visible in equipment qualification (IQ/OQ/PQ) and process validation practices.
Key observations:
- Risk-Based Validation: There is a clear expectation that the validation effort aligns with system and process risk. Over-validation of low-risk systems and under-validation of critical processes are both being challenged. Inspectors are looking for documented justification of scope and depth.
- Lifecycle Approach: Validation is no longer viewed as a one-time activity. Greater emphasis is placed on maintaining a validated state through ongoing monitoring, periodic review, and effective change control. Continued Process Verification (CPV) is expected where applicable.
- Commissioning vs Qualification: A common gap is the lack of a clear distinction between commissioning activities and formal qualification. Evidence is expected to show what was leveraged from commissioning and how it was assessed for GMP impact.
- Acceptance Criteria: Generic or overly broad acceptance criteria are being questioned. Acceptance limits are expected to be scientifically justified and linked to process requirements and product quality.
- Data Integrity in Validation: Raw data, test execution records, and deviations during qualification are under closer scrutiny. Any re-testing or undocumented corrections are likely to be raised as findings.
- Traceability: End-to-end traceability from User Requirements Specification (URS) through to qualification testing and final reports is expected. Gaps in traceability matrices are a recurring issue.
Alignment is increasingly evident with expectations from the European Medicines Agency and the U.S. Food and Drug Administration, particularly regarding lifecycle validation and science-based justification.
Recommended actions:
- Reassess validation strategies using a documented risk-based approach
- Clearly separate commissioning and qualification activities with defined deliverables
- Strengthen acceptance criteria with scientific and process-based rationale
- Implement or enhance Continued Process Verification programs
- Ensure full traceability across validation documentation
- Review handling of deviations and re-testing within qualification protocols
Organizations that continue to rely on templated protocols without process understanding or risk justification are increasingly exposed during inspections.
Validation is being assessed not by the volume of documentation, but by the strength of its rationale and its connection to product quality and patient safety.
